Health Winners & Losers: Geron

In other analyst action, RBC Capital Markets dropped its price target for development stage biopharmaceutical company Molecular Insight Pharmaceuticals(MIPI Quote - Cramer on MIPI - Stock Picks) to $14 from $18, but the stock was relatively unaffected, gaining 1.9% to $8.54 on very light volume.

In earnings, Abraxis BioScience (ABII Quote - Cramer on ABII - Stock Picks) said it turned a first-quarter profit of $4.3 million, or 11 cents a share, vs. a loss of 14 cents a share in the year-ago quarter. Revenue rose 14% to $82.1 million, from $71.9 million, leveraged by higher sales of its breast cancer drug Abraxane. Shares were off by nearly 1% at $62.65 on very light volume.

« Previous Page

1 2

Next Page »